MIST241115P7500
- 0.00
- 0.000.00%
Milestone Pharmaceuticals Newsroom
Milestone Pharmaceuticals' CARDAMYST: A Game Changer in PSVT Treatment With Significant Market Potential
Individual Investors Account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Ownership, While Institutions Account for 46%
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $9
TD Cowen Sticks to Its Buy Rating for Milestone Pharmaceuticals (MIST)
Express News | Milestone Pharmaceuticals Inc: 500-Patient Phase 3 Trial (JX02002) Met Its Primary Endpoint
Express News | Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results From the Phase 3 Study of Etripamil in PSVT in China
Milestone Pharmaceuticals Welcomes New Directors and Auditor
Press Release: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors
Express News | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors
Milestone Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
Rodman & Renshaw Initiates Milestone Pharmaceuticals(MIST.US) With Buy Rating, Announces Target Price $9
Milestone Wins Buy at Rodman & Renshaw on Potential Cardamyst Approval
Milestone Pharmaceuticals: A Buy Rating on CARDAMYST's Market Potential and FDA Progress
Express News | Milestone Pharmaceuticals Shares Are Trading Higher After Rodman & Renshaw Initiated Coverage on the Stock With a Buy Rating and Announced a $9 Price Target
Express News | Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9
Piper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals GAAP EPS of -$0.14
Milestone Pharmaceuticals' Promising Drug Advancements
Milestone Pharmaceuticals Eyes 2025 for CARDAMYST Launch